PD-Rx Pharmaceuticals, Inc. Completes Licensing Agreement With CliniDATA

OKLAHOMA CITY, Nov. 16 /PRNewswire-FirstCall/ -- PD-Rx Pharmaceuticals, Inc. , a publicly held corporation, today announced that is has completed the Licensing Agreements with CliniDATA, a division of Etreby, to offer to its customers a proprietary database of licensed products that will include drug information and therapeutic files.

The CliniDATA data base information will be offered through a sublicensing agreement as a web base portal and integrated within the PD-Rx Net Software platform that is currently available on the market. The integrated package will provide general information to the patient population and assist them in the proper use, storage, and compliance with the medications that have been prescribed.

ABOUT THE COMPANIES:

PD-Rx offers pharmaceutical and management strategies to the healthcare industry. Our management strategies focus on new products, solid business partners, and the specialized segment of the pharmaceutical industry. As a licensed FDA manufacturer and packager, PD-Rx offers a full spectrum of medications and specialized services. Our goal is to develop a matrix of cost containment tools and products that we can merge into any healthcare network to enhance patient care and improve managed care organizations bottom line. We provide proprietary products and prepackaged medications that are viewed by patient, insurance payers, and healthcare providers as a progressive and responsive practice.

CliniDATA Source, a subsidiary of Etreby Computer Company, develops and maintains drug and clinical information systems for the healthcare industry. CliniDATA Source provides drug file information and clinical databases that serve as the clinical engine and decision support tools for pharmacy and medical practice applications as well as drug information websites.

This press release contains "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward- looking statements involve known and unknown risks and uncertainties or other factors, which may cause actual results, performance or achievements expressed or implied by such forward-looking statements to vary from those forecast or implied in this release. Factors that might cause such a difference include, without limitation, decline in demand for the company's products or services, and the effect of general economic conditions and factors affecting the industry.

CONTACT: Jack L. McCall, EVP & COO of PD-Rx Pharmaceuticals, Inc.,+1-405-942-3040, or jack@pdrx.com